Experimental drug shows promise in advanced kidney cancer

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumor fails to respond to the cutting edge therapy. The study, presented today at the European Cancer Conference in Barcelona, showed that the experimental drug, axitinib, shrank tumors and delayed progression of the disease in a group of patients who are among the toughest to treat.

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <em> <strong> <cite><p><br><i><b><center><ul><li><div><html5:figure><html5:figcaption>
  • Lines and paragraphs break automatically.

More information about formatting options

CAPTCHA
Sorry, we know you're not a spambot, but they're out there